The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.

Jimmy L ZhaoKarim FizaziFred SaadKim N ChiMary-Ellen TaplinCora N Sternberg Andrew J Armstrong Johann S de BonoWilliam T DugganHoward I Scher

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Patients with mCRPC benefited from enzalutamide treatment independent of CCU, but CCU was associated with worse baseline prognostic factors and outcomes.

Keyphrases

prostate cancer
phase iii
prognostic factors
clinical trial
radical prostatectomy
open label
metabolic syndrome
double blind
data analysis